<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">problendo</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы Эндокринологии</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0375-9660</issn><issn pub-type="epub">2308-1430</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/probl20115743-6</article-id><article-id custom-type="elpub" pub-id-type="custom">problendo-4566</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Об информативности очень высоких уровней пролактина при пролактинсекретирующих макроаденомах гипофиза (наблюдения из практики)</article-title><trans-title-group xml:lang="en"><trans-title>About informative value of very high prolactin levels in patients presenting with prolactin-secreting pituitary macroadenomas (clinical observations)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Astaf'eva</surname><given-names>L I</given-names></name></name-alternatives><email xlink:type="simple">last@nsi.ru</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Kadashev</surname><given-names>B A</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Tenedieva</surname><given-names>V D</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Moshkin</surname><given-names>A V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Shifrin</surname><given-names>M A</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>15</day><month>08</month><year>2011</year></pub-date><volume>57</volume><issue>4</issue><issue-title>ТОМ 57, №4 (2011)</issue-title><fpage>3</fpage><lpage>6</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Astaf'eva L.I., Kadashev B.A., Tenedieva V.D., Moshkin A.V., Shifrin M.A., 2011</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="ru">Astaf'eva L.I., Kadashev B.A., Tenedieva V.D., Moshkin A.V., Shifrin M.A.</copyright-holder><copyright-holder xml:lang="en">Astaf'eva L.I., Kadashev B.A., Tenedieva V.D., Moshkin A.V., Shifrin M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.probl-endojournals.ru/jour/article/view/4566">https://www.probl-endojournals.ru/jour/article/view/4566</self-uri><abstract><p>Средний уровень пролактина (ПРЛ) у пациентов с микропролактиномой обычно cоставляет 3-4 тыс. мЕд/л, а у больных с макропролактиномой - 10-20 тыс. мЕд/л. При гигантских пролактинсекретирующих аденомах гипофиза уровень пролактина может превышать 1 млн мЕд/л. Для его выявления необходимо значительное разведение плазмы. Несмотря на возможные связанные с высоким разведением ошибки, такие исследования позволяют выявить тенденцию к снижению уровня пролактина, что необходимо для быстрого выбора метода лечения (хирургический, медикаментозный) в критических ситуациях. В работе приведены описания нескольких случаев гигантских пролактином с крайне высоким уровнем ПРЛ и его динамикой на фоне лечения каберголином.</p></abstract><trans-abstract xml:lang="en"><p>The mean blood prolactin level in patients with microprolactinomas is usually 3000-4000 mU/l compared with 10 000-20 000 mU/l in cases presenting with macroprolactinomas. It may be as high as 1 mln mU/l and more in patients with a giant tumour. The measurement of prolactin levels requires laboratory studies of strongly diluted plasma samples. Significant dilution is fraught with erroneous prolactin levels: nevertheless, this approach allows a tendency toward decreasing concentration of prolactin to be revealed which may be important for taking rapid decision concerning the choice of the treatment strategy (either surgical or medicamental) especially in critical situations. A few clinical cases of giant prolactinomas with an unusually high blood prolactin level are described with reference to its dynamics during treatment with cabergoline.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>макропролактинома</kwd><kwd>уровень пролактина</kwd><kwd>гигантская аденома гипофиза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>macroprolactinoma</kwd><kwd>prolactin levels</kwd><kwd>giant pituitary adenoma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Casanueva F.F., Molitch M.E., Schlechte J.A. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 2: 265-273.</mixed-citation><mixed-citation xml:lang="en">Casanueva F.F., Molitch M.E., Schlechte J.A. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 2: 265-273.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Colao A., Di Sarno A., Cappabianca P. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 20: 349: 21: 2023-2033.</mixed-citation><mixed-citation xml:lang="en">Colao A., Di Sarno A., Cappabianca P. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 20: 349: 21: 2023-2033.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Colao A., Sarno A.D., Cappabianca P. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003; 148: 3: 325-331.</mixed-citation><mixed-citation xml:lang="en">Colao A., Sarno A.D., Cappabianca P. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003; 148: 3: 325-331.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kars M., Pereira A.M., Smit J.W., Romijn J.A. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 2009; 20: 4: 387-393. Epub 2008 Dec 30.</mixed-citation><mixed-citation xml:lang="en">Kars M., Pereira A.M., Smit J.W., Romijn J.A. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 2009; 20: 4: 387-393. Epub 2008 Dec 30.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schlechte J.A. Prolactinoma. N Engl J Med 2003; 349: 2035-2041.</mixed-citation><mixed-citation xml:lang="en">Schlechte J.A. Prolactinoma. N Engl J Med 2003; 349: 2035-2041.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Acharya S.V., Gopal R.A., Menon P.S., Bandgar T.R. Giant prolactinoma and effectiveness of medical management. Endocr Pract 2010; 16: 1: 42-46.</mixed-citation><mixed-citation xml:lang="en">Acharya S.V., Gopal R.A., Menon P.S., Bandgar T.R. Giant prolactinoma and effectiveness of medical management. Endocr Pract 2010; 16: 1: 42-46.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Batrinos M.L. Extensive personal experience. Validation of prolactin levels in menstrual disorders and in prolactinomas. Hormones (Athens) 2009; 8: 4: 258-266.</mixed-citation><mixed-citation xml:lang="en">Batrinos M.L. Extensive personal experience. Validation of prolactin levels in menstrual disorders and in prolactinomas. Hormones (Athens) 2009; 8: 4: 258-266.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Beckers A. СD "Pituitary adenomas" 2007, Graph Med Ltd.</mixed-citation><mixed-citation xml:lang="en">Beckers A. СD "Pituitary adenomas" 2007, Graph Med Ltd.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cho E.H., Lee S.A., Chung J.Y., Koh E.H. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 2009; 24: 5: 874-878.</mixed-citation><mixed-citation xml:lang="en">Cho E.H., Lee S.A., Chung J.Y., Koh E.H. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 2009; 24: 5: 874-878.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 5: 485-534. Epub 2006 May 26.</mixed-citation><mixed-citation xml:lang="en">Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 5: 485-534. Epub 2006 May 26.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kawabata Y., Ueno Y., Horikawa F., Miyake H. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. Surg Neurol 2008; 69: 1: 85-88.</mixed-citation><mixed-citation xml:lang="en">Kawabata Y., Ueno Y., Horikawa F., Miyake H. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. Surg Neurol 2008; 69: 1: 85-88.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Petrossians P., de Herder W., Kwekkeboom D. Malignant prolactinoma discovered by D2 receptor imaging. J Clin Endocrinol Metab 2000; 85: 1: 398-401.</mixed-citation><mixed-citation xml:lang="en">Petrossians P., de Herder W., Kwekkeboom D. Malignant prolactinoma discovered by D2 receptor imaging. J Clin Endocrinol Metab 2000; 85: 1: 398-401.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Schöfl C., Schöfl-Siegert B., Karstens J.H. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary 2002; 5: 4: 261-265.</mixed-citation><mixed-citation xml:lang="en">Schöfl C., Schöfl-Siegert B., Karstens J.H. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary 2002; 5: 4: 261-265.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Shimon I., Benbassat C., Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007; 156: 2: 225-231.</mixed-citation><mixed-citation xml:lang="en">Shimon I., Benbassat C., Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007; 156: 2: 225-231.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Shrivastava R.K., Arginteanu M.S., King W.A. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002; 97: 299-306.</mixed-citation><mixed-citation xml:lang="en">Shrivastava R.K., Arginteanu M.S., King W.A. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002; 97: 299-306.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yang M.Y., Shen C.C., Ho W.L. Treatments of multi-invasive giant prolactinoma. J Clin Neurosci 2004; 11: 1: 70-75.</mixed-citation><mixed-citation xml:lang="en">Yang M.Y., Shen C.C., Ho W.L. Treatments of multi-invasive giant prolactinoma. J Clin Neurosci 2004; 11: 1: 70-75.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция к анализатору IMMULITE 2000 (Siemens Healthcare Diagnostics Inc., США).</mixed-citation><mixed-citation xml:lang="en">Инструкция к анализатору IMMULITE 2000 (Siemens Healthcare Diagnostics Inc., США).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция к набору реагента MMULITE 2000 PROLACTIN (PIL2KPR-15, 2006-12-29) (Siemens Medical Solutions Diagnostics).</mixed-citation><mixed-citation xml:lang="en">Инструкция к набору реагента MMULITE 2000 PROLACTIN (PIL2KPR-15, 2006-12-29) (Siemens Medical Solutions Diagnostics).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Астафьева Л.И., Кадашев Б.А., Калинин П.Л. и др. Клиническая картина, диагностика и результаты первичной медикаментозной терапии больших и гигантских пролактинсекретирующих аденом гипофиза. Вопросы нейрохирургии 2008; 4: 36-39.</mixed-citation><mixed-citation xml:lang="en">Астафьева Л.И., Кадашев Б.А., Калинин П.Л. и др. Клиническая картина, диагностика и результаты первичной медикаментозной терапии больших и гигантских пролактинсекретирующих аденом гипофиза. Вопросы нейрохирургии 2008; 4: 36-39.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Астафьева Л.И., Кадашев Б.А., Калинин П.Л. и др. Выбор тактики лечения гигантских пролактинсекретирующих аденом гипофиза. Вопросы нейрохирургии 2009; 2: 23-29.</mixed-citation><mixed-citation xml:lang="en">Астафьева Л.И., Кадашев Б.А., Калинин П.Л. и др. Выбор тактики лечения гигантских пролактинсекретирующих аденом гипофиза. Вопросы нейрохирургии 2009; 2: 23-29.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Астафьева Л.И., Кадашев Б.А., Кутин М.А. Изменение размеров пролактинсекретирующих макроаденом гипофиза на фоне терапии агонистами дофамина. "Вестник Российского Научного Центра рентгенрадиологии". 30 сентября 2010 года http://vestnik.rncrr.ru/vestnik/v10/papers/astafieva_v10.htm.</mixed-citation><mixed-citation xml:lang="en">Астафьева Л.И., Кадашев Б.А., Кутин М.А. Изменение размеров пролактинсекретирующих макроаденом гипофиза на фоне терапии агонистами дофамина. "Вестник Российского Научного Центра рентгенрадиологии". 30 сентября 2010 года http://vestnik.rncrr.ru/vestnik/v10/papers/astafieva_v10.htm.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
